Ionis Pharmaceuticals IONS Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's unrealized gains on investments?
- Ionis Pharmaceuticals (IONS) reported unrealized gains on investments of $1.11M in Q1 2026.
- How has Ionis Pharmaceuticals's unrealized gains on investments changed year-over-year?
- Ionis Pharmaceuticals's unrealized gains on investments decreased by 55.8% year-over-year, from $2.5M to $1.11M.
- What is the long-term trend for Ionis Pharmaceuticals's unrealized gains on investments?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's unrealized gains on investments has grown at a 35.2% compound annual growth rate (CAGR), from $1.26M to $4.22M.
- What does unrealized gains on investments mean?
- The total paper profit on investment securities that have not yet been sold.
- How do you interpret unrealized gains on investments?
- An increase indicates favorable market conditions for the company's fixed-income holdings, potentially signaling higher portfolio value.
- How does unrealized gains on investments compare across companies?
- Commonly tracked by peers to monitor the performance of treasury management strategies.